Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 206,117,233 papers from all fields of science
Search
Sign In
Create Free Account
PF 03814735
Known as:
Aurora Kinase Inhibitor PF-03814735
, PF-03814735
, PF03814735
An aurora kinase inhibitor with potential antineoplastic activity. PF-03814735 binds to and inhibits aurora kinases, serine-threonine kinases that…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Aurora Kinase A
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Toward In Vitro Epigenetic Drug Design for Thyroid Cancer: The Promise of PF-03814735, an Aurora Kinase Inhibitor.
Sevim Dalva-Aydemir
,
C. Akyerli
,
Şirin Yüksel
,
Hilal Keskin
,
M. C. Yakıcıer
Omics : a journal of integrative biology
2019
Corpus ID: 202745699
Thyroid cancer (TC) is a very common malignancy worldwide. Chief among the innovative molecular drug targets for TC are…
Expand
2019
2019
Characterization of in vitro metabolism of focal adhesion kinase inhibitors by LC/MS/MS
Quan Chi
,
Ling Wang
,
D. Xie
,
Xian Wang
Journal of pharmaceutical and biomedical analysis
2019
Corpus ID: 73501559
Review
2015
Review
2015
Structural Biology Insight for the Design of Sub-type Selective Aurora Kinase Inhibitors.
Sailu Sarvagalla
,
M. Coumar
Current cancer drug targets
2015
Corpus ID: 32052807
Aurora kinase A, B and C, are key regulators of mitosis and are over expressed in many of the human cancers, making them an ideal…
Expand
2013
2013
An exploration of pathways involved in lung carcinoid progression using gene expression profiling.
Dorian R. A. Swarts
,
L. van Neste
,
+10 authors
E. Speel
Carcinogenesis
2013
Corpus ID: 13516989
Pulmonary carcinoids comprise a well-differentiated subset of neuroendocrine tumors usually associated with a favorable prognosis…
Expand
Highly Cited
2012
Highly Cited
2012
An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735
K. Hook
,
S. Garza
,
+12 authors
A. Pavlícek
Molecular Cancer Therapeutics
2012
Corpus ID: 17465451
PF-03814735 is a novel, reversible inhibitor of Aurora kinases A and B that finished a phase I clinical trial for the treatment…
Expand
2011
2011
Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours.
P. Schöffski
,
Suzanne F. Jones
,
+9 authors
H. Burris
European journal of cancer
2011
Corpus ID: 33280556
Highly Cited
2010
Highly Cited
2010
PF-03814735, an Orally Bioavailable Small Molecule Aurora Kinase Inhibitor for Cancer Therapy
J. Jani
,
Joel T. Arcari
,
+19 authors
J. Jakubczak
Molecular Cancer Therapeutics
2010
Corpus ID: 18202364
The Aurora family of highly related serine/threonine kinases plays a key role in the regulation of mitosis. Aurora1 and Aurora2…
Expand
2008
2008
Phase I accelerated dose-escalation, pharmacokinetic (PK) and pharmacodynamic study of PF-03814735, an oral aurora kinase inhibitor, in patients with advanced solid tumors: Preliminary results
Suzanne F. Jones
,
H. Burris
,
+7 authors
P. Schöffski
2008
Corpus ID: 74022798
2517 Background: Aurora kinases are a family of kinases that play a crucial role in regulating segregation of chromosomes and…
Expand
2008
2008
282 POSTER Preliminary results of a Phase I accelerated dose-escalation, pharmacokinetic and pharmacodynamic study of PF-03814735, an oral Aurora kinase A and B inhibitor, in patients with advanced…
P. Schöffski
,
H. Dumez
,
+7 authors
H. Burris
2008
Corpus ID: 72912994
2008
2008
Gateways to clinical trials.
A. Tomillero
,
M. A. Moral
Methods and findings in experimental and clinical…
2008
Corpus ID: 26153196
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE